Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.39 |
| ▸ | USP7 | Q93009 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.31 |
| ▸ | PDE4A | P27815 | 2/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL891636 | 1.00 | MAPT (0.39) | MAPTCYP11B2USP7RECQLPDE4B | |
| SCHEMBL22814329 | 1.00 | MAPT (0.39) | MAPTCYP11B2USP7RECQLPDE4B | |
| SCHEMBL18884152 | 0.87 | CYP11B2 (0.36) | MAPTCYP11B2USP7RECQL | |
| SCHEMBL18393034 | 0.85 | CYP11B2 (0.50) | MAPTCYP11B2USP7RECQLPDE2A | |
| SCHEMBL1769870 | 0.85 | CYP11B2 (0.35) | MAPTCYP11B2USP7RECQL | |
| SCHEMBL30708125 | 0.84 | MAPT (0.33) | MAPTCYP11B2USP7 | |
| SCHEMBL20604443 | 0.81 | APLNR (0.39) | MAPTCYP11B2USP7PDE4BPDE4A | |
| SCHEMBL20604447 | 0.81 | APLNR (0.39) | MAPTCYP11B2USP7PDE4BPDE4A | |
| SCHEMBL84898 | 0.79 | MAPT (0.37) | MAPTGAA | |
| SCHEMBL18572976 | 0.75 | CYP11B2 (0.33) | CYP11B2USP7PDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630530-B2 | FGFR inhibitor compound and use thereof | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2026-05-19 | — | — | US | disclosed |
| EP-4261213-B1 | FGFR INHIBITOR COMPOUND AND USE THEREOF | SHENZHEN KANGSU PHARMACEUTICAL TECH CO LTD (CN) | 2026-04-15 | — | — | EP | disclosed |
| US-20250340533-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | TYRA BIOSCIENCES INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12264149-B2 | Indazole compounds as kinase inhibitors | TYRA BIOSCIENCES, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| EP-4186894-B1 | FGFR INHIBITOR COMPOUND AND USE THEREOF | HENAN MEDINNO PHARMACEUTICAL TECH CO LTD (CN) | 2024-12-04 | — | — | EP | disclosed |
| US-12071428-B2 | Indazole compounds as kinase inhibitors | TYRA BIOSCIENCES, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| WO-2024137742-A1 | COMPOUNDS AND COMPOSITIONS AS FGFR3 DEGRADERS AND USES THEREOF | BLUEPRINT MEDICINES CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240208941-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | TYRA BIOSCIENCES, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240109865-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | TYRA BIOSCIENCES, INC. | 2024-04-04 | — | — | US | disclosed |
| WO-2023229295-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING PHENYLPROPENE DERIVATIVE AS ACTIVE INGREDIENT | 재단법인 대구경북첨단의료산업진흥재단 | 2023-11-30 | — | — | WO | disclosed |
| CN-103153983-A | Crystalline (r) - (e) -2- (4- (2- (5- (1- (3, 5 -dichloropyridin-4 -yl) ethoxy) - 1H - indazol - 3 - yl) vinyl) -1 H- pyrazol- 1 -yl) ethanol and its use as FGFR inhibitor | LILLY CO ELI | 2013-06-12 | — | — | CN | disclosed |
| EP-2427449-B1 | VINYL INDAZOLYL COMPOUNDS | LILLY CO ELI (US) | 2013-04-03 | — | — | EP | disclosed |
| US-8268869-B2 | Vinyl indazolyl compounds | ELI LILLY AND COMPANY (US) | 2012-09-18 | — | — | US | disclosed |
| CN-102421769-A | Vinyl indazolyl compounds | LILLY CO ELI (US) | 2012-04-18 | — | — | CN | disclosed |
| WO-2012047699-A1 | CRYSTALLINE (R) - (E) -2- (4- (2- (5- (1- (3, 5 -DICHLOROPYRIDIN-4 -YL) ETHOXY) - 1H - INDAZOL - 3 - YL) VINYL) -1 H- PYRAZOL- 1 -YL) ETHANOL AND ITS USE AS FGFR INHIBITOR | ELI LILLY AND COMPANY (US) | 2012-04-12 | — | — | WO | disclosed |
| US-20120083511-A1 | CRYSTALLINE (R)-(E)-2-(4-(2-(5-(1-(3,5-DICHLOROPYRIDIN-4-YL)ETHOXY)-1H-INDAZOL-3-YL)VINYL)-1H-PYRAZOL-1-YL)ETHANOL | ELI LILLY AND COMPANY (US) | 2012-04-05 | — | — | US | disclosed |
| EP-2427449-A1 | VINYL INDAZOLYL COMPOUNDS | Eli Lilly and Company (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2011141756-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2011-11-17 | — | — | WO | disclosed |
| WO-2010129509-A1 | VINYL INDAZOLYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286209-A1 | VINYL INDAZOLYL COMPOUNDS | ELI LILLY AND COMPANY | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630530-B2 | FGFR inhibitor compound and use thereof | FGFR3, FGFR1, FGFR4 | MAPT 2238/4885CYP11B2 423/4885USP7 3700/4885 |
| US-12071428-B2 | Indazole compounds as kinase inhibitors | FGFR1, FGFR2, FGFR3 | MAPT 1463/4885CYP11B2 960/4885USP7 4252/4885 |
| US-20240208941-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | FGFR1, FGFR2, FGFR3 | MAPT 1463/4885CYP11B2 960/4885USP7 4252/4885 |
| US-20120083511-A1 | CRYSTALLINE (R)-(E)-2-(4-(2-(5-(1-(3,5-DICHLOROPYRIDIN-4-YL)ETHOXY)-1H-INDAZOL-3-YL)VINYL)-1H-PYRAZOL-1-YL)ETHANOL | ADH1A, ADH1C, ADH5 | MAPT 2271/4885CYP11B2 3764/4885USP7 4107/4885 |
| US-20250340533-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | FGFR1, FGFR2, FGFR3 | MAPT 1463/4885CYP11B2 960/4885USP7 4252/4885 |
| US-12264149-B2 | Indazole compounds as kinase inhibitors | FGFR1, FGFR2, FGFR3 | MAPT 1463/4885CYP11B2 960/4885USP7 4252/4885 |
| US-20100286209-A1 | VINYL INDAZOLYL COMPOUNDS | VHL, IDH3B, IDH3A | MAPT 3942/4885CYP11B2 1183/4885USP7 3304/4885 |
| US-20240109865-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | FGFR1, FGFR2, FGFR3 | MAPT 1463/4885CYP11B2 960/4885USP7 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.